Discover investment opportunities in Biotech Stocks List using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Stocks List using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Stocks List using our Smart AI Filter.
10 stocks found for "Biotech Stocks List"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.06 | ±44.4% | -272.1 | 0.00% | |||
0.70 | ±46.8% | 1.5 | 0.00% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.63 | ±35.0% | 27.1 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.44 | ±32.3% | 11.1 | 0.00% | |||
0.60 | ±39.2% | 20.8 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.22 | ±27.3% | 15.0 | 2.83% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How are biotech stocks like GILD and AMGN typically impacted by economic downturns?
A: Biotech stocks such as GILD (Gilead Sciences) and AMGN (Amgen) generally show resilience during economic downturns due to the consistent demand for healthcare products. However, R&D funding and investor sentiment can be affected, impacting smaller biotechs particularly.
Q: What dividend opportunities do biotech companies offer, particularly VRTX and INCY?
A: Most biotech companies, including VRTX (Vertex Pharmaceuticals) and INCY (Incyte Corporation), reinvest earnings into research and development, often leading to limited dividend offerings. Investors seeking dividends might need to consider larger, more mature biotechs with stable cash flows.
Q: What are the geographical advantages for companies like BIIB in the biotech sector?
A: Biotech companies like BIIB (Biogen) often benefit from being located in hubs such as Boston or San Francisco, which provide proximity to leading research institutions, top-tier universities, and a rich network of clinical trials and talent.
Q: How does the competitive landscape affect the growth potential of companies like SRPT in gene therapy?
A: SRPT (Sarepta Therapeutics), focusing on gene therapy, faces competition from both established biotech firms and emerging startups. The rapidly evolving technology and potential for breakthroughs drive growth potential but also introduce significant risk and volatility.
Q: What structural advantages does REGN have over other biotechs?
A: REGN (Regeneron Pharmaceuticals) differentiates itself through its proprietary VelociSuite technology, which enhances its drug discovery process. This platform provides a competitive edge in developing novel therapeutics, allowing REGN to maintain a robust pipeline.
Q: Are stocks like CRSP considered volatile relative to traditional healthcare stocks?
A: Yes, stocks like CRSP (CRISPR Therapeutics), involved in cutting-edge technologies such as gene editing, can be more volatile than traditional healthcare stocks, due to high R&D expenditures, regulatory approvals, and market acceptance uncertainties.
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments by the pharmaceutical industry as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country.
Read more